AVA-201 / Adverum Biotech - LARVOL DELTA

Avalon GloboCare Provides Updates on its Lead Clinical Programs in CAR-T Therapy and Exosome-Based Regenerative Therapeutics (GlobeNewswire, Avalon GloboCare Corp.) - Next-generation, transposon-engineered, multi-targeted CAR-T candidate, AVA-101, has entered process development and validation phase; expect to launch first-in-human trial in Q1 2020. Accelerate clinical development of exosome-based oncology and regenerative therapeutic programs, AVA-201 and AVA-202. FREEHOLD, N.J., July 15, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced an update on its four clinical programs in cellular therapy, including AVA-001 and AVA-101, that leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy for immuno-oncology, as well as AVA-201 and AVA-202 exploring novel development with stem cell derived exosomes.

Clinical • New trial • Preclinical